Enfusion Inc. (ENFN)
Enfusion Statistics
Share Statistics
Enfusion has 94.8M shares outstanding. The number of shares has increased by 5.01% in one year.
Shares Outstanding | 94.8M |
Shares Change (YoY) | 5.01% |
Shares Change (QoQ) | 1.25% |
Owned by Institutions (%) | 98.11% |
Shares Floating | 39.86M |
Failed to Deliver (FTD) Shares | 1.64K |
FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 711.66K, so 0.75% of the outstanding shares have been sold short.
Short Interest | 711.66K |
Short % of Shares Out | 0.75% |
Short % of Float | 1.46% |
Short Ratio (days to cover) | 0.74 |
Valuation Ratios
The PE ratio is 335.84 and the forward PE ratio is 38.89. Enfusion's PEG ratio is -4.14.
PE Ratio | 335.84 |
Forward PE | 38.89 |
PS Ratio | 4.7 |
Forward PS | 3.4 |
PB Ratio | 12.95 |
P/FCF Ratio | 30.54 |
PEG Ratio | -4.14 |
Enterprise Valuation
Enfusion Inc. has an Enterprise Value (EV) of 835.39M.
EV / Earnings | 295.92 |
EV / Sales | 4.14 |
EV / EBITDA | 135.73 |
EV / EBIT | 135.73 |
EV / FCF | 26.91 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.28.
Current Ratio | 3.42 |
Quick Ratio | 3.42 |
Debt / Equity | 0.28 |
Total Debt / Capitalization | 21.72 |
Cash Flow / Debt | 1.71 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.04% and return on capital (ROIC) is 1.96%.
Return on Equity (ROE) | 0.04% |
Return on Assets (ROA) | 0.02% |
Return on Capital (ROIC) | 1.96% |
Revenue Per Employee | $176,387.58 |
Profits Per Employee | $2,469.82 |
Employee Count | 1,143 |
Asset Turnover | 1.41 |
Inventory Turnover | n/a |
Taxes
Income Tax | 4.57M |
Effective Tax Rate | 0.62 |
Stock Price Statistics
The stock price has increased by 20.43% in the last 52 weeks. The beta is 0.95, so Enfusion's price volatility has been higher than the market average.
Beta | 0.95 |
52-Week Price Change | 20.43% |
50-Day Moving Average | 11.17 |
200-Day Moving Average | 9.65 |
Relative Strength Index (RSI) | 49.39 |
Average Volume (20 Days) | 1.09M |
Income Statement
In the last 12 months, Enfusion had revenue of 201.61M and earned 2.82M in profits. Earnings per share was 0.02.
Revenue | 201.61M |
Gross Profit | 136.74M |
Operating Income | 6.16M |
Net Income | 2.82M |
EBITDA | 6.16M |
EBIT | 6.16M |
Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 54.48M in cash and 20.31M in debt, giving a net cash position of 34.17M.
Cash & Cash Equivalents | 54.48M |
Total Debt | 20.31M |
Net Cash | 34.17M |
Retained Earnings | -170.11M |
Total Assets | 143.26M |
Working Capital | 66.19M |
Cash Flow
In the last 12 months, operating cash flow was 34.68M and capital expenditures -3.63M, giving a free cash flow of 31.05M.
Operating Cash Flow | 34.68M |
Capital Expenditures | -3.63M |
Free Cash Flow | 31.05M |
FCF Per Share | 0.34 |
Margins
Gross margin is 67.82%, with operating and profit margins of 3.05% and 1.4%.
Gross Margin | 67.82% |
Operating Margin | 3.05% |
Pretax Margin | 3.66% |
Profit Margin | 1.4% |
EBITDA Margin | 3.05% |
EBIT Margin | 3.05% |
FCF Margin | 15.4% |
Dividends & Yields
ENFN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 0.18% |
FCF Yield | 2.94% |
Analyst Forecast
The average price target for ENFN is $12.25, which is 10% higher than the current price. The consensus rating is "Hold".
Price Target | $12.25 |
Price Target Difference | 10% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Scores
Altman Z-Score | 14.92 |
Piotroski F-Score | 5 |